Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 14/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NMBR | P28336 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2034215 | 0.88 | SIRT2 (0.46) | SIRT2 | |
| SCHEMBL1038850 | 0.87 | SIRT2 (0.52) | SIRT2ALDH1A1KDM4ENMBR | |
| SCHEMBL4383636 | 0.85 | SIRT2 (0.45) | SIRT2 | |
| SCHEMBL9259069 | 0.84 | CYP4F2 (0.46) | SIRT2ALDH1A1 | |
| SCHEMBL877052 | 0.82 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL8447651 | 0.80 | SIRT2 (0.51) | SIRT2NMBR | |
| SCHEMBL9789313 | 0.80 | SIRT2 (0.42) | SIRT2ALDH1A1 | |
| SCHEMBL23278623 | 0.80 | SIRT2 (0.46) | SIRT2NMBR | |
| SCHEMBL9239485 | 0.80 | SIRT2 (0.44) | SIRT2NMBR | |
| SCHEMBL8070031 | 0.79 | ALDH1A1 (0.49) | SIRT2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | LEONARD DANIELE MARIE (US) | 2004-09-02 | — | — | US | disclosed |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | WARNER-LAMBERT COMPANY | 2003-12-18 | — | — | US | disclosed |
| EP-1276724-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2003-01-22 | — | — | EP | disclosed |
| WO-2001079179-A2 | DIHYDRO-2H-NAPHTHALENE-1-ONE INHIBITORS OF RAS FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 2001-10-25 | — | — | WO | disclosed |
| US-6156746-A | 1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171844-A1 | Dihydro-2H-naphthalene-1-one inhibitors of ras farnesyl transferase | NRAS, HRAS, FNTB | SIRT2 964/4885ALDH1A1 1270/4885CYP2C9 1432/4885 |
| US-20030232790-A1 | Dihydro-2h-napthalene-1-one inhibitors of ras farnesyl transferase | NRAS, FNTA, CYP46A1 | SIRT2 755/4885ALDH1A1 491/4885CYP2C9 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.